Analysts' Top 5 Price Targets of June 23, 2025
Reading Time: 3 minutes
Evolent Health [US30050B1017]: UBS reaffirms Buy rating with a price target of $15 (62% upside potential) In a press release, Evolent Health confirmed that the cost developments in oncology are continuing to perform better than expected. This news should reassure investors, as high oncology costs have been considered a potential risk to profitability. Additionally, the company announced that it has received a new credit commitment from Ares. Evolent also reaffirmed its guidance for adjusted EBITDA for both the second quarter and the full year...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
